S&P 500   3,625.73 (-0.27%)
DOW   29,870.08 (-0.59%)
QQQ   295.27 (+0.27%)
AAPL   115.94 (+0.67%)
MSFT   212.95 (-0.43%)
FB   274.57 (-0.85%)
GOOGL   1,763.46 (-0.02%)
AMZN   3,175.65 (+1.85%)
TSLA   563.53 (+1.47%)
NVDA   525.45 (+1.38%)
BABA   276.03 (-1.40%)
CGC   26.96 (-0.04%)
GE   10.49 (+0.38%)
MU   62.99 (-1.50%)
AMD   86.25 (+1.39%)
T   28.99 (-0.82%)
NIO   53.15 (-0.67%)
F   9.12 (-3.49%)
ACB   8.66 (-6.18%)
NFLX   481.84 (-0.22%)
GILD   59.56 (-1.15%)
BA   219.59 (+0.50%)
DIS   148.73 (-1.82%)
S&P 500   3,625.73 (-0.27%)
DOW   29,870.08 (-0.59%)
QQQ   295.27 (+0.27%)
AAPL   115.94 (+0.67%)
MSFT   212.95 (-0.43%)
FB   274.57 (-0.85%)
GOOGL   1,763.46 (-0.02%)
AMZN   3,175.65 (+1.85%)
TSLA   563.53 (+1.47%)
NVDA   525.45 (+1.38%)
BABA   276.03 (-1.40%)
CGC   26.96 (-0.04%)
GE   10.49 (+0.38%)
MU   62.99 (-1.50%)
AMD   86.25 (+1.39%)
T   28.99 (-0.82%)
NIO   53.15 (-0.67%)
F   9.12 (-3.49%)
ACB   8.66 (-6.18%)
NFLX   481.84 (-0.22%)
GILD   59.56 (-1.15%)
BA   219.59 (+0.50%)
DIS   148.73 (-1.82%)
S&P 500   3,625.73 (-0.27%)
DOW   29,870.08 (-0.59%)
QQQ   295.27 (+0.27%)
AAPL   115.94 (+0.67%)
MSFT   212.95 (-0.43%)
FB   274.57 (-0.85%)
GOOGL   1,763.46 (-0.02%)
AMZN   3,175.65 (+1.85%)
TSLA   563.53 (+1.47%)
NVDA   525.45 (+1.38%)
BABA   276.03 (-1.40%)
CGC   26.96 (-0.04%)
GE   10.49 (+0.38%)
MU   62.99 (-1.50%)
AMD   86.25 (+1.39%)
T   28.99 (-0.82%)
NIO   53.15 (-0.67%)
F   9.12 (-3.49%)
ACB   8.66 (-6.18%)
NFLX   481.84 (-0.22%)
GILD   59.56 (-1.15%)
BA   219.59 (+0.50%)
DIS   148.73 (-1.82%)
S&P 500   3,625.73 (-0.27%)
DOW   29,870.08 (-0.59%)
QQQ   295.27 (+0.27%)
AAPL   115.94 (+0.67%)
MSFT   212.95 (-0.43%)
FB   274.57 (-0.85%)
GOOGL   1,763.46 (-0.02%)
AMZN   3,175.65 (+1.85%)
TSLA   563.53 (+1.47%)
NVDA   525.45 (+1.38%)
BABA   276.03 (-1.40%)
CGC   26.96 (-0.04%)
GE   10.49 (+0.38%)
MU   62.99 (-1.50%)
AMD   86.25 (+1.39%)
T   28.99 (-0.82%)
NIO   53.15 (-0.67%)
F   9.12 (-3.49%)
ACB   8.66 (-6.18%)
NFLX   481.84 (-0.22%)
GILD   59.56 (-1.15%)
BA   219.59 (+0.50%)
DIS   148.73 (-1.82%)
Log in
NASDAQ:NVCR

NovoCure Stock Forecast, Price & News

$117.08
-2.33 (-1.95 %)
(As of 11/25/2020 12:03 PM ET)
Add
Compare
Today's Range
$115.53
Now: $117.08▼
$123.57
50-Day Range
$112.16
MA: $126.55▼
$138.72
52-Week Range
$53.40
Now: $117.08▼
$140.89
Volume45,039 shs
Average Volume1.01 million shs
Market Capitalization$11.92 billion
P/E Ratio616.24
Dividend YieldN/A
Beta1.37
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and NovoTTF-100L, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products that are in Phase 2 pilot and Phase 3 pivotal trials for brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.
Read More
NovoCure logo

Beat the Market (BTM) Rank™

Analyst Opinion: 2.2Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.66 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVCR
Previous Symbol
CUSIPN/A
CIK1645113
Webwww.novocure.com
Phone44-0-15-3475-6700
Employees782

Debt

Debt-to-Equity RatioN/A
Current Ratio4.02
Quick Ratio3.74

Price-To-Earnings

Trailing P/E Ratio616.24
Forward P/E Ratio557.52
P/E GrowthN/A

Sales & Book Value

Annual Sales$351.32 million
Price / Sales33.92
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.02 per share
Price / Book38.77

Profitability

EPS (Most Recent Fiscal Year)($0.07)
Net Income$-7,230,000.00
Net Margins4.26%
Return on Equity7.40%
Return on Assets3.94%

Miscellaneous

Outstanding Shares101,797,000
Market Cap$11.92 billion
Next Earnings Date2/25/2021 (Estimated)
OptionableOptionable
$117.08
-2.33 (-1.95 %)
(As of 11/25/2020 12:03 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NovoCure (NASDAQ:NVCR) Frequently Asked Questions

How has NovoCure's stock been impacted by Coronavirus (COVID-19)?

NovoCure's stock was trading at $67.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NVCR shares have increased by 73.9% and is now trading at $117.20.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of NovoCure?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last year. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for NovoCure.

What stocks does MarketBeat like better than NovoCure?

Wall Street analysts have given NovoCure a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NovoCure wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is NovoCure's next earnings date?

NovoCure is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for NovoCure.

How were NovoCure's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) issued its quarterly earnings data on Thursday, October, 29th. The medical equipment provider reported $0.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.04 by $0.05. The medical equipment provider earned $132.70 million during the quarter, compared to analyst estimates of $120.02 million. NovoCure had a return on equity of 7.40% and a net margin of 4.26%. The business's quarterly revenue was up 44.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.02 EPS.
View NovoCure's earnings history.

What price target have analysts set for NVCR?

10 brokerages have issued 1-year price objectives for NovoCure's stock. Their forecasts range from $58.00 to $150.00. On average, they expect NovoCure's share price to reach $102.25 in the next twelve months. This suggests that the stock has a possible downside of 12.8%.
View analysts' price targets for NovoCure.

Who are some of NovoCure's key competitors?

Some companies that are related to NovoCure include Boston Scientific (BSX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Fresenius SE & Co. KGaA (FSNUY), Teleflex (TFX), Insulet (PODD), Abiomed (ABMD), Penumbra (PEN), iRhythm Technologies (IRTC), Hill-Rom (HRC), Globus Medical (GMED), Haemonetics (HAE), Nevro (NVRO) and Tandem Diabetes Care (TNDM).
View all competitors.

What other stocks do shareholders of NovoCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy Partners (VNOM), Roku (ROKU), salesforce.com (CRM) and Square (SQ).

Who are NovoCure's key executives?

NovoCure's management team includes the following people:
  • Mr. William F. Doyle, Exec. Chairman (Age 58, Pay $1.66M)
  • Mr. Asaf Danziger, Pres, CEO & Director (Age 54, Pay $1.69M)
  • Mr. Wilhelmus C. M. Groenhuysen, Chief Operating Officer (Age 62, Pay $1.02M)
  • Mr. Pritesh Shah, Chief Commercial Officer (Age 42, Pay $725.6k)
  • Prof. Yoram Palti, Founder & CTO (Age 82)
  • Ms. Ashley Cordova, CFO & VP of Investor Relations
  • Mr. Todd C. Longsworth, Gen. Counsel (Age 45)
  • Dr. Ely Benaim, Chief Medical Officer (Age 59)
  • Mr. Uri Weinberg M.D., Ph.D., Chief Science Officer
  • Mr. Frank Leonard, Chief Devel. Officer

What is NovoCure's stock symbol?

NovoCure trades on the NASDAQ under the ticker symbol "NVCR."

Who are NovoCure's major shareholders?

NovoCure's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.87%), Morgan Stanley (1.30%), State Street Corp (1.13%), Wells Fargo & Company MN (1.07%), Charles Schwab Investment Management Inc. (0.57%) and Rhenman & Partners Asset Management AB (0.41%). Company insiders that own NovoCure stock include Asaf Danziger, Ashley Cordova, Charles G Phillips III, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends for NovoCure.

Which major investors are selling NovoCure stock?

NVCR stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Cubist Systematic Strategies LLC, Squarepoint Ops LLC, Los Angeles Capital Management & Equity Research Inc., C WorldWide Group Holding A S, Peregrine Capital Management LLC, BNP Paribas Arbitrage SA, and Allianz Asset Management GmbH. Company insiders that have sold NovoCure company stock in the last year include Asaf Danziger, Ashley Cordova, Charles G Phillips III, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen, and William F Doyle.
View insider buying and selling activity for NovoCure.

Which major investors are buying NovoCure stock?

NVCR stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Charles Schwab Investment Management Inc., Scout Investments Inc., Federated Hermes Inc., State Street Corp, Voloridge Investment Management LLC, Hodges Capital Management Inc., and Rhenman & Partners Asset Management AB.
View insider buying and selling activity for NovoCure.

How do I buy shares of NovoCure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NovoCure's stock price today?

One share of NVCR stock can currently be purchased for approximately $117.20.

How big of a company is NovoCure?

NovoCure has a market capitalization of $11.93 billion and generates $351.32 million in revenue each year. The medical equipment provider earns $-7,230,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. NovoCure employs 782 workers across the globe.

What is NovoCure's official website?

The official website for NovoCure is www.novocure.com.

How can I contact NovoCure?

NovoCure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]

This page was last updated on 11/25/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.